223 related articles for article (PubMed ID: 23912226)
1. The role of tumor necrosis factor-α in the pathogenesis of vitiligo.
Camara-Lemarroy CR; Salas-Alanis JC
Am J Clin Dermatol; 2013 Oct; 14(5):343-50. PubMed ID: 23912226
[TBL] [Abstract][Full Text] [Related]
2. A patient with psoriasis and vitiligo treated with etanercept.
Campanati A; Giuliodori K; Ganzetti G; Liberati G; Offidani AM
Am J Clin Dermatol; 2010; 11 Suppl 1():46-8. PubMed ID: 20586509
[TBL] [Abstract][Full Text] [Related]
3. Novel approaches to vitiligo treatment via modulation of mTOR and NF-κB pathways in human skin melanocytes.
Wan J; Lin F; Zhang W; Xu A; DeGiorgis J; Lu H; Wan Y
Int J Biol Sci; 2017; 13(3):391-400. PubMed ID: 28367103
[TBL] [Abstract][Full Text] [Related]
4. Tumor Necrosis Factor-alpha affects melanocyte survival and melanin synthesis via multiple pathways in vitiligo.
Singh M; Mansuri MS; Kadam A; Palit SP; Dwivedi M; Laddha NC; Begum R
Cytokine; 2021 Apr; 140():155432. PubMed ID: 33517195
[TBL] [Abstract][Full Text] [Related]
5. Autoimmunity as an aetiological factor in vitiligo.
Rezaei N; Gavalas NG; Weetman AP; Kemp EH
J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):865-76. PubMed ID: 17658994
[TBL] [Abstract][Full Text] [Related]
6. Association of interferon-gamma and tumor necrosis factor alpha polymorphisms with susceptibility to vitiligo in Iranian patients.
Namian AM; Shahbaz S; Salmanpoor R; Namazi MR; Dehghani F; Kamali-Sarvestani E
Arch Dermatol Res; 2009 Jan; 301(1):21-5. PubMed ID: 18820938
[TBL] [Abstract][Full Text] [Related]
7. Basic fibroblast growth factor and tumour necrosis factor alpha in vitiligo and other hypopigmented disorders: suggestive possible therapeutic targets.
Seif El Nasr H; Shaker OG; Fawzi MM; El-Hanafi G
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):103-8. PubMed ID: 22151832
[TBL] [Abstract][Full Text] [Related]
8. Use of anti-tumor necrosis factor agents: a possible therapy for vitiligo.
Lv Y; Li Q; Wang L; Gao T
Med Hypotheses; 2009 May; 72(5):546-7. PubMed ID: 19201101
[TBL] [Abstract][Full Text] [Related]
9. Endothelin-1 enhances the proliferation of normal human melanocytes in a paradoxical manner from the TNF-α-inhibited condition, but tacrolimus promotes exclusively the cellular migration without proliferation: a proposed action mechanism for combination therapy of phototherapy and topical tacrolimus in vitiligo treatment.
Lee KY; Jeon SY; Hong JW; Choi KW; Lee CY; Choi SJ; Kim JH; Song KH; Kim KH
J Eur Acad Dermatol Venereol; 2013 May; 27(5):609-16. PubMed ID: 22404745
[TBL] [Abstract][Full Text] [Related]
10. Increased Tumor Necrosis Factor (TNF)-α and its promoter polymorphisms correlate with disease progression and higher susceptibility towards vitiligo.
Laddha NC; Dwivedi M; Begum R
PLoS One; 2012 Dec; 7(12):e52298. PubMed ID: 23284977
[TBL] [Abstract][Full Text] [Related]
11. Lack of association with TNF-alpha-308 promoter polymorphism in patients with vitiligo.
Yazici AC; Erdal ME; Kaya TI; Ikizoglu G; Savasoglu K; Camdeviren H; Tursen U
Arch Dermatol Res; 2006 Jun; 298(1):46-9. PubMed ID: 16691430
[TBL] [Abstract][Full Text] [Related]
12. Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo.
Boukhedouni N; Martins C; Darrigade AS; Drullion C; Rambert J; Barrault C; Garnier J; Jacquemin C; Thiolat D; Lucchese F; Morel F; Ezzedine K; Taieb A; Bernard FX; Seneschal J; Boniface K
JCI Insight; 2020 Jun; 5(11):. PubMed ID: 32369451
[TBL] [Abstract][Full Text] [Related]
13. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines.
Grimes PE; Morris R; Avaniss-Aghajani E; Soriano T; Meraz M; Metzger A
J Am Acad Dermatol; 2004 Jul; 51(1):52-61. PubMed ID: 15243524
[TBL] [Abstract][Full Text] [Related]
14. Vitiligo: pathogenetic hypotheses and targets for current therapies.
Guerra L; Dellambra E; Brescia S; Raskovic D
Curr Drug Metab; 2010 Jun; 11(5):451-67. PubMed ID: 20540698
[TBL] [Abstract][Full Text] [Related]
15. The combination of tumour necrosis factor-α -308A and interleukin-10 -1082G gene polymorphisms and increased serum levels of related cytokines: susceptibility to vitiligo.
Aydıngöz IE; Kanmaz-Özer M; Gedikbaşi A; Vural P; Doğru-Abbasoğlu S; Uysal M
Clin Exp Dermatol; 2015 Jan; 40(1):71-7. PubMed ID: 25283497
[TBL] [Abstract][Full Text] [Related]
16. Cytokines: the yin and yang of vitiligo pathogenesis.
Singh M; Kotnis A; Jadeja SD; Mondal A; Mansuri MS; Begum R
Expert Rev Clin Immunol; 2019 Feb; 15(2):177-188. PubMed ID: 30462555
[TBL] [Abstract][Full Text] [Related]
17. Vitiligo: pathomechanisms and genetic polymorphism of susceptible genes.
Shajil EM; Chatterjee S; Agrawal D; Bagchi T; Begum R
Indian J Exp Biol; 2006 Jul; 44(7):526-39. PubMed ID: 16872041
[TBL] [Abstract][Full Text] [Related]
18. New insights into immune mechanisms of vitiligo.
Boniface K; Taïeb A; Seneschal J
G Ital Dermatol Venereol; 2016 Feb; 151(1):44-54. PubMed ID: 26512930
[TBL] [Abstract][Full Text] [Related]
19. CD8+ T cells from vitiligo perilesional margins induce autologous melanocyte apoptosis.
Wu J; Zhou M; Wan Y; Xu A
Mol Med Rep; 2013 Jan; 7(1):237-41. PubMed ID: 23042234
[TBL] [Abstract][Full Text] [Related]
20. Translational Research in Vitiligo.
Katz EL; Harris JE
Front Immunol; 2021; 12():624517. PubMed ID: 33737930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
